Lonza Group AG (LONN) - Cash Flow Conversion Efficiency

Latest as of June 2026: 0.081x

Based on the latest financial reports, Lonza Group AG (LONN) has a cash flow conversion efficiency ratio of 0.081x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF660.00 Million ≈ $834.42 Million USD) by net assets (CHF8.15 Billion ≈ $10.31 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Lonza Group AG (LONN) market capitalisation for the company's overall valuation and market capitalisation.

Lonza Group AG - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Lonza Group AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Lonza Group AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lonza Group AG ranked by their cash flow conversion efficiency. Explore Lonza Group AG earnings quality ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Microchip Technology Inc
NASDAQ:MCHP
0.040x
Powszechna Kasa Oszczednosci Bank Polski SA
WAR:PKO
0.037x
LEGRAND UNSP.ARD 1/5 EO 4
F:LRC0
0.033x
Legrand SA
PA:LR
0.059x
EQT AB (publ)
ST:EQT
0.035x
Flex Ltd
NASDAQ:FLEX
0.080x
CSL LTD SPON.ADR 2
F:CSJA
N/A
JD.com Inc Adr
NASDAQ:JD
0.002x

Annual Cash Flow Conversion Efficiency for Lonza Group AG (2004–2025)

The table below shows the annual cash flow conversion efficiency of Lonza Group AG from 2004 to 2025. View LONN stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CHF9.19 Billion
≈ $11.61 Billion
CHF1.17 Billion
≈ $1.48 Billion
0.127x -6.23%
2024-12-31 CHF9.39 Billion
≈ $11.87 Billion
CHF1.27 Billion
≈ $1.61 Billion
0.136x -6.80%
2023-12-31 CHF9.51 Billion
≈ $12.03 Billion
CHF1.39 Billion
≈ $1.75 Billion
0.146x +52.24%
2022-12-31 CHF10.66 Billion
≈ $13.48 Billion
CHF1.02 Billion
≈ $1.29 Billion
0.096x -22.80%
2021-12-31 CHF9.82 Billion
≈ $12.42 Billion
CHF1.22 Billion
≈ $1.54 Billion
0.124x -24.52%
2020-12-31 CHF6.88 Billion
≈ $8.70 Billion
CHF1.13 Billion
≈ $1.43 Billion
0.164x +9.29%
2019-12-31 CHF6.57 Billion
≈ $8.30 Billion
CHF986.00 Million
≈ $1.25 Billion
0.150x -12.69%
2018-12-31 CHF6.29 Billion
≈ $7.95 Billion
CHF1.08 Billion
≈ $1.37 Billion
0.172x +26.43%
2017-12-31 CHF6.18 Billion
≈ $7.81 Billion
CHF841.00 Million
≈ $1.06 Billion
0.136x -57.39%
2016-12-31 CHF2.35 Billion
≈ $2.98 Billion
CHF752.00 Million
≈ $950.73 Million
0.319x -8.00%
2015-12-31 CHF2.13 Billion
≈ $2.70 Billion
CHF741.00 Million
≈ $936.82 Million
0.347x +53.06%
2014-12-31 CHF2.13 Billion
≈ $2.69 Billion
CHF483.00 Million
≈ $610.64 Million
0.227x -7.65%
2013-12-31 CHF2.13 Billion
≈ $2.69 Billion
CHF522.00 Million
≈ $659.95 Million
0.246x -16.80%
2012-12-31 CHF2.41 Billion
≈ $3.04 Billion
CHF710.00 Million
≈ $897.63 Million
0.295x +214.59%
2011-12-31 CHF2.36 Billion
≈ $2.98 Billion
CHF221.00 Million
≈ $279.40 Million
0.094x -55.40%
2010-12-31 CHF2.39 Billion
≈ $3.02 Billion
CHF502.00 Million
≈ $634.66 Million
0.210x +19.06%
2009-12-31 CHF2.39 Billion
≈ $3.02 Billion
CHF422.00 Million
≈ $533.52 Million
0.177x +80.58%
2008-12-31 CHF1.79 Billion
≈ $2.26 Billion
CHF175.00 Million
≈ $221.25 Million
0.098x -72.54%
2007-12-31 CHF1.81 Billion
≈ $2.29 Billion
CHF644.00 Million
≈ $814.19 Million
0.356x +34.68%
2006-12-31 CHF1.61 Billion
≈ $2.03 Billion
CHF425.00 Million
≈ $537.31 Million
0.264x -4.59%
2005-12-31 CHF1.49 Billion
≈ $1.88 Billion
CHF413.00 Million
≈ $522.14 Million
0.277x +100.10%
2004-12-31 CHF1.28 Billion
≈ $1.62 Billion
CHF178.00 Million
≈ $225.04 Million
0.139x --

About Lonza Group AG

SW:LONN Switzerland Diagnostics & Research
Market Cap
$50.08 Billion
CHF39.62 Billion CHF
Market Cap Rank
#693 Global
#10 in Switzerland
Share Price
CHF567.20
Change (1 day)
-2.54%
52-Week Range
CHF467.40 - CHF593.80
All Time High
CHF769.70
About

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biol… Read more